When it comes to unforeseen research disruptions, the most successful lab operations professionals hope for “if” but plan for “when.” Yet, a survey found that only 51% of businesses have continuity plans. Business continuity plans (BCPs) ensure labs can maintain critical functions, quickly resume normal operations, and prevent the loss of valuable research in the event of interruptions. This guide explores why and how to create a business continuity plan for your laboratory. - Business continuity plans for labs- Benefits of a lab business continuity plan- Cheat sheet: 12 key elements for…

Riding the biotech wave: A durable bet for real estate? Biotechnology – using biological science and living systems to develop new products – is often associated with pharmaceuticals. In reality, its impact extends far beyond human healthcare. Biotech innovations are quietly transforming agriculture, energy, materials, and even computing. From engineered crops and lab-grown meats to bio-based chemicals and renewable fuels, the use of biology as technology now permeates diverse industries. It is central to tackling some of the world's most critical challenges. Structural tailwinds and…

Why the “biology-first, modality-agnostic” era is eclipsing yesterday’s size-based dogma From bucketed modalities to a continuum mindset For most of the modern drug-discovery era, chemists and biologists organised therapeutics along a rigid, size-driven taxonomy: small (< 500 Da), peptide, protein, gene, cell. That reductionist view served medicinal chemistry well when Lipinski’s rule-of-five was the dominant heuristic and gate-keeper of oral success, and when antibodies, oligonucleotides and viral vectors each lived in their own, distant technological silos. Yet 2025’s pipeline tells a…

Anne Horgan, Partner at Cambridge Innovation Capital, talks about what makes her tick as an investor.  She will chair the discussion on Nailing the Fundraise at BioBeat25.   Co-organisers, Alisa Molotova, Start-up Mentor, and Miranda Weston-Smith, BioBeat founder chat with her about her role.  Q: How did you become an investor? Anne: I would love to answer this question by saying that this was the result of a well thought-out 10 year career plan…the reality is somewhat less straightforward! I am a scientist by training and after a PhD in organic chemistry at the…

by Tony Jones, CEO, One Nucleus Trusting Your NeighboursContinuing down the thought process of the importance of nurturing your local ambassadors to enable your international success described in last month’s blog, I seek to explore the value of ensuring your company is not just recognised but also well understood within your local ecosystem, since nurturing success is a two-way process between all parties. It’s one thing for your neighbours to recognise you and know who you are; it is a step further for your neighbours to understand your goals and challenges unless you are open enough to…

by Monalisa Breazu, Learning & Development Administrator, One Nucleus At a recent One Nucleus roundtable, a diverse group of professionals came together to talk candidly about this exact issue. From HR and hiring leads to scientists, educators, and entrepreneurs, we unpacked what’s working, what’s broken, and what needs to change. Here’s what we learned and what we need to start doing differently. From Science Backgrounds to Skills-First Hiring A recurring theme was the debate around what constitutes a "science background“. Many attendees emphasised that having a PhD or even a STEM degree…

Priya Mande, CEO of RNAvate, is leading the discussion on Biotech and Partnering Hotspots at BioBeat25. Organisers Anne Horgan, Partner at Cambridge Innovation Capital, Alisa Molotova, Start-up Mentor and Miranda Weston-Smith, BioBeat Founder quiz her about how she got into her role. How did you get into biotech? I recall people telling me that I was crazy to give up my Pharma role and perks (eg company car) to join biotech which was a new world of higher risk, limited resource/ cash and no desk (really)…! However, I wanted to explore working in a small company where I could feel my…

Whether it’s your first time or your fifth, lab relocation is no walk in the park. There are a lot of expensive, complicated balls to juggle and what you don’t know can cause serious problems down the line. In a recent webinar, Nathan Foorman, facilities operations and engineering expert, and Lindsey Fitzgerald, ZAGENO senior account executive, hosted biotech and pharma lab managers and procurement for a deep dive into lab move best practices. Using insights gained from numerous moves, they shared tips to sidestep common pitfalls and prevent budget-draining, time-wasting mistakes. Common Lab…

Guest blog by Nick Hutchinson, Associate Vice President Business Development, Just - Evotec BiologicsBallroom J.POD® Redmond, WA. Just – Evotec Biologics You would be forgiven for thinking that little has changed in biomanufacturing in the past 20 years. The sector is stuck using the same production methods and facility designs that emerged at the turn of the century. These approaches create risks and inefficiencies in the production pipeline, including: High manufacturing costs Difficulty in adapting to demand Expensive and risk-prone commercial development process A lack of innovation in…

One Nucleus is always conscious that our member companies are constantly mindful of the need to be international given the nature of the life sciences sector, innovation and the unmet medical needs they seek to address. Supporting our members in their international endeavours takes many forms that are more obvious, such as those described below. Complementing these more direct interventions however is something we do not often discuss or highlight which is the efforts to enable our members to involve their network neighbours in their cause, recruiting them as their ambassadors when they are…